Badrinath R. Konety, MD, MBA, FACSProfessor and Chair, Dept. of UrologyDougherty Family Chair in Urologic OncologyAssociate Director for Clinical Affairs, Masonic Cancer CenterUniversity of MinnesotaMMC 394, 420 Delaware StMinneapolis MN 55455, USA Sam S. Chang, MD, FACSProfessor of Urologic SurgeryPatricia and Rodes Hart Chair of Urologic SurgeryDepartment of Urologic SurgeryVanderbilt University Medical CenterMCN A 1302, VUMCNashville, TN 37232, USA

From the book reviews: "The target audience is researchers, clinicians, trainees, allied health professionals, and medical students. Given the emphasis and specificity of the chapters on early stage bladder cancer, this book seems most geared to urologists and urology trainees. ... This is a very easy to use, clearly and expertly written, case- and clinical scenario-based reference that will be helpful to all who treat and study bladder cancer." (Jean Hoffman-Censits, Doody's Book Reviews, March, 2015)

• Epidemiology and natural history.- Screening for Bladder Cancer.- Pathology and Staging: Histopathology and Cytopathology.- Pathology and Staging: Genetics and Molecular Biology.- Imaging in Localized and Advanced Bladder Cancer.- New Imaging Techniques in Staging of Urothelial Carcinoma of the Bladder.- Socioeconomic issues and improved quality of care.- Quality of life measures.- Prognostication and risk assessment.- Clinical trials and emerging therapeutic strategies in bladder cancer.- Improved diagnostic techniques.- Clinical scenario: Microscopic hematuria and atypical cytology in a 68 year old man with normal upper tract imaging.- Localized surgical therapy and surveillance.- Clinical Scenario: Initial high grade Ta tumor.- Clinical Scenario: Recurrent Ta tumor.- Clinical Scenario: Rapidly growing, high volume, low grade Ta tumor.- Clinical Scenario: Low grade T1 tumor.- Intravesical therapy.- Clinical Scenario: Initial CIS.- Management of BCG Recurrent Bladder Cancer.- Clinical Scenario: Persistent CIS and HIGH Grade Ta Bladder Cancer after BCG.- Maurizio Brausi.- Clinical Scenario: Presentation and Management of Significant Side Effects from Bacillus Calmette-Guérin Bladder Instillation.- Guideline-based management of non-muscle invasive bladder cancer: comparison of the AUA, EAU, ICUD and NCCN guidelines.- Open Radical Cystectomy.- Robotic cystectomy.- Clinical Scenario: T2 bladder tumor.- Urinary Diversion: Open and robotic techniques.- Chemoradiotherapy.- Clinical Scenario: 53 year-old man with a solitary, 2 cm, high-grade T2 tumor and focal CIS in the bladder dome who wants bladder preservation.- Management of Bladder Cancer, role of chemotherapy and controversies surrounding its application.- Clinical Scenario: Large volume, non metastatic T2 bladder tumor.- The role of pelvic lymphadenectomy at the time of radical cystectomy for bladder cancer.- Clinical Scenario: Unexpected positive nodes at radical cystectomy.- Surveillance andmonitoring.- Clinical Scenario: The Role of Perioperative Chemotherapy.- Management of Bladder Cancer with Pelvic Nodal Metastases After Complete Response to Chemotherapy.- Guideline based management muscle-invasive bladder cancer: NCCN, ICUD and EAU.

Badrinath R. Konety, MD, MBA, FACSProfessor and Chair, Dept. of UrologyDougherty Family Chair in Urologic OncologyAssociate Director for Clinical Affairs, Masonic Cancer CenterUniversity of MinnesotaMMC 394, 420 Delaware StMinneapolis MN 55455, USA Sam S. Chang, MD, FACSProfessor of Urologic SurgeryPatricia and Rodes Hart Chair of Urologic SurgeryDepartment of Urologic SurgeryVanderbilt University Medical CenterMCN A 1302, VUMCNashville, TN 37232, USA

From the book reviews: "The target audience is researchers, clinicians, trainees, allied health professionals, and medical students. Given the emphasis and specificity of the chapters on early stage bladder cancer, this book seems most geared to urologists and urology trainees. ... This is a very easy to use, clearly and expertly written, case- and clinical scenario-based reference that will be helpful to all who treat and study bladder cancer." (Jean Hoffman-Censits, Doody's Book Reviews, March, 2015)

• Epidemiology and natural history.- Screening for Bladder Cancer.- Pathology and Staging: Histopathology and Cytopathology.- Pathology and Staging: Genetics and Molecular Biology.- Imaging in Localized and Advanced Bladder Cancer.- New Imaging Techniques in Staging of Urothelial Carcinoma of the Bladder.- Socioeconomic issues and improved quality of care.- Quality of life measures.- Prognostication and risk assessment.- Clinical trials and emerging therapeutic strategies in bladder cancer.- Improved diagnostic techniques.- Clinical scenario: Microscopic hematuria and atypical cytology in a 68 year old man with normal upper tract imaging.- Localized surgical therapy and surveillance.- Clinical Scenario: Initial high grade Ta tumor.- Clinical Scenario: Recurrent Ta tumor.- Clinical Scenario: Rapidly growing, high volume, low grade Ta tumor.- Clinical Scenario: Low grade T1 tumor.- Intravesical therapy.- Clinical Scenario: Initial CIS.- Management of BCG Recurrent Bladder Cancer.- Clinical Scenario: Persistent CIS and HIGH Grade Ta Bladder Cancer after BCG.- Maurizio Brausi.- Clinical Scenario: Presentation and Management of Significant Side Effects from Bacillus Calmette-Guérin Bladder Instillation.- Guideline-based management of non-muscle invasive bladder cancer: comparison of the AUA, EAU, ICUD and NCCN guidelines.- Open Radical Cystectomy.- Robotic cystectomy.- Clinical Scenario: T2 bladder tumor.- Urinary Diversion: Open and robotic techniques.- Chemoradiotherapy.- Clinical Scenario: 53 year-old man with a solitary, 2 cm, high-grade T2 tumor and focal CIS in the bladder dome who wants bladder preservation.- Management of Bladder Cancer, role of chemotherapy and controversies surrounding its application.- Clinical Scenario: Large volume, non metastatic T2 bladder tumor.- The role of pelvic lymphadenectomy at the time of radical cystectomy for bladder cancer.- Clinical Scenario: Unexpected positive nodes at radical cystectomy.- Surveillance andmonitoring.- Clinical Scenario: The Role of Perioperative Chemotherapy.- Management of Bladder Cancer with Pelvic Nodal Metastases After Complete Response to Chemotherapy.- Guideline based management muscle-invasive bladder cancer: NCCN, ICUD and EAU.

Badrinath R. Konety, MD, MBA, FACSProfessor and Chair, Dept. of UrologyDougherty Family Chair in Urologic OncologyAssociate Director for Clinical Affairs, Masonic Cancer CenterUniversity of MinnesotaMMC 394, 420 Delaware StMinneapolis MN 55455, USA Sam S. Chang, MD, FACSProfessor of Urologic SurgeryPatricia and Rodes Hart Chair of Urologic SurgeryDepartment of Urologic SurgeryVanderbilt University Medical CenterMCN A 1302, VUMCNashville, TN 37232, USA

From the book reviews: "The target audience is researchers, clinicians, trainees, allied health professionals, and medical students. Given the emphasis and specificity of the chapters on early stage bladder cancer, this book seems most geared to urologists and urology trainees. ... This is a very easy to use, clearly and expertly written, case- and clinical scenario-based reference that will be helpful to all who treat and study bladder cancer." (Jean Hoffman-Censits, Doody's Book Reviews, March, 2015)

• Epidemiology and natural history.- Screening for Bladder Cancer.- Pathology and Staging: Histopathology and Cytopathology.- Pathology and Staging: Genetics and Molecular Biology.- Imaging in Localized and Advanced Bladder Cancer.- New Imaging Techniques in Staging of Urothelial Carcinoma of the Bladder.- Socioeconomic issues and improved quality of care.- Quality of life measures.- Prognostication and risk assessment.- Clinical trials and emerging therapeutic strategies in bladder cancer.- Improved diagnostic techniques.- Clinical scenario: Microscopic hematuria and atypical cytology in a 68 year old man with normal upper tract imaging.- Localized surgical therapy and surveillance.- Clinical Scenario: Initial high grade Ta tumor.- Clinical Scenario: Recurrent Ta tumor.- Clinical Scenario: Rapidly growing, high volume, low grade Ta tumor.- Clinical Scenario: Low grade T1 tumor.- Intravesical therapy.- Clinical Scenario: Initial CIS.- Management of BCG Recurrent Bladder Cancer.- Clinical Scenario: Persistent CIS and HIGH Grade Ta Bladder Cancer after BCG.- Maurizio Brausi.- Clinical Scenario: Presentation and Management of Significant Side Effects from Bacillus Calmette-Guérin Bladder Instillation.- Guideline-based management of non-muscle invasive bladder cancer: comparison of the AUA, EAU, ICUD and NCCN guidelines.- Open Radical Cystectomy.- Robotic cystectomy.- Clinical Scenario: T2 bladder tumor.- Urinary Diversion: Open and robotic techniques.- Chemoradiotherapy.- Clinical Scenario: 53 year-old man with a solitary, 2 cm, high-grade T2 tumor and focal CIS in the bladder dome who wants bladder preservation.- Management of Bladder Cancer, role of chemotherapy and controversies surrounding its application.- Clinical Scenario: Large volume, non metastatic T2 bladder tumor.- The role of pelvic lymphadenectomy at the time of radical cystectomy for bladder cancer.- Clinical Scenario: Unexpected positive nodes at radical cystectomy.- Surveillance andmonitoring.- Clinical Scenario: The Role of Perioperative Chemotherapy.- Management of Bladder Cancer with Pelvic Nodal Metastases After Complete Response to Chemotherapy.- Guideline based management muscle-invasive bladder cancer: NCCN, ICUD and EAU.